As the auto industry rapidly changes, distinctions that were once clear in terms of which cars or manufacturers are truly "American" have blurred. Domestic brands have been bought and sold by foreign companies, while many Japanese automakers boast significant production from domestically located factories.�
Cars.com has created its own system, the American-Made Index, which considers a variety of factors in determining which vehicles have the most red, white, and blue in their veins.�
While rankings like this may seem irrelevant to investors, big-ticket purchases such as automobiles and homes are often done with the heart and not the head. Many people buy domestically manufactured vehicles on principle, and being "more American" can be as important a car's price and features.
A high ranking in one direction or another can boost loyalty and pricing power as well.
Considering all of these factors, I selected the best automaker for a recovering U.S. auto industry in the following slide show.
Top 5 Penny Companies To Watch For 2015: GFI Group Inc. (GFIG)
GFI Group Inc. provides wholesale brokerage, clearing, electronic execution, and trading support products for financial markets. The company offers brokerage and trade execution services, clearing services, market data and trading platform, and other software products to institutional customers. The company provides brokerage services in fixed income derivatives, bond instruments, and other related products; financial instruments, including foreign exchange options, exotic options, non-U.S. Dollar interest rate swaps and options, repurchase agreements, forward and non-deliverable forward contracts, and government and municipal bond options; cash-based and derivative equity products, such as the U.S. domestic and international equity stocks, global depositary receipts, American depositary receipts, and equity derivatives; and cash-based and derivative commodity, and energy products comprising oil, natural gas, biofuel, electricity, wet and dry freight derivatives, dry physi cal freight, precious metals, coal, property derivatives, emissions, ethanol, and soft commodities. It also offers clearing, brokerage, settlement, and back-office services to proprietary traders, brokers, market makers, and hedge funds; provides capital to start-up trading groups, small hedge funds, market-makers, and individual traders; licenses multi-asset class electronic trading and order management software to brokers, exchanges, and traders in the commodities, fixed income, currencies, and equities markets; and offers FENICS Professional, a suite of price discovery, price distribution, trading, risk management, and straight-through processing components. The company primarily serves investment and commercial banks, large corporations, asset managers, insurance companies, hedge funds, and proprietary trading firms in the Americas; Europe, the Middle East, and Africa; and Asia. GFI Group Inc. was founded in 1987 and is headquartered in New York, New York.
Advisors' Opinion:- [By Jayson Derrick]
CME Group (NYSE: CME) has agreed to acquire GFI Group (NASDAQ: GFIG) for $4.55 per share and will immediately sell it's wholesale brokerage and clearing business back to a group led by GFI Management. CME will retain GFI Group's Trayport which provides trading software in the European energy markets as well as FENICS, a provider of price discovery, analytics, risk-management and workflow connectivity services for over the counter foreign exchange options markets. Shares of CME Group gained 0.44 percent, closing at $75.83 while shares of GFI Group surged to new 52-week highs of $4.50 before closing the day at $4.47, up 43.73 percent.
Hot Japanese Companies To Buy Right Now: Dyax Corp.(DYAX)
Dyax Corp., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel biotherapeutics for unmet medical needs in the United States. The company utilizes its proprietary drug discovery technology, known as phage display, to identify antibody, small protein, and peptide compounds. It markets KALBITOR (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. Dyax Corp. also provides KALBITOR Access program, which offers treatment support service for patients with HAE and their healthcare providers. In addition, the company is developing a pipeline of 17 product candidates, including 4 product candidates in Phase III clinical trial, 4 product candidates in Phase II clinical trial, and 9 product candidates in Phase 1 clinical trial for the treatment of atherosclerosis, multiple sclerosis, and oncology diseases. Further, it provides library licenses to use its phage display libr aries in connection with their internal therapeutic development programs; performs funded research for various collaborators; and offers patent licenses to other biopharmaceutical and pharmaceutical companies to use its phage display patents to discover and develop biologic compounds for use in specified fields. The company has strategic partnership agreement with Defiante Farmaceutica S.A. to develop and commercialize subcutaneous ecallantide for the treatment of HAE and other therapeutic indications in Europe, North Africa, the Middle East, and Russia; an agreement with CMIC Co., Ltd to develop and commercialize subcutaneous ecallantide for the treatment of HAE and other angioedema indications in Japan; and an license and collaboration agreement with Cubist Pharmaceuticals, Inc. to develop and commercialize the formulation of ecallantide for the reduction of blood loss during surgery in North America and Europe. Dyax Corp. was founded in 1989 and is headquartered in Cambri dge, Massachusetts.
Advisors' Opinion:- [By Jake L'Ecuyer]
Leading and Lagging Sectors
In trading on Tuesday, healthcare shares were relative leaders, up on the day by about 1.35 percent. Meanwhile, top gainers in the sector included Allergan (NYSE: AGN), up 15.7 percent, and Dyax (NASDAQ: DYAX), up 12.5 percent. Energy shares dropped around 0.06 percent in today's trading. - [By Travis Hoium]
What: Shares of Dyax (NASDAQ: DYAX ) lost 34% of their value today, falling off a cliff after first-quarter earnings came out.
So what: First-quarter net sales increased slightly from a year ago, to $12.0 million, but analysts expected $16.0 million in revenue, so this is a huge miss. It's no wonder that net loss of $11.2 million equates to $0.11 per share, more than double the $0.05 per share loss analysts expected.�
- [By Jake L'Ecuyer]
Dyax (NASDAQ: DYAX) shares tumbled 10.39 percent to $9.10 after the company priced 8 million shares at $9.25 per share.
Raptor Pharmaceuticals (NASDAQ: RPTP) was down, falling 10.04 percent to $13.31 after the company reported Q4 results. Raptor Pharmaceutical posted a Q4 loss of $0.20 per share, versus the projected loss of $0.16 per share.
- [By Jake L'Ecuyer]
Dyax (NASDAQ: DYAX) shares tumbled 9.85 percent to $9.15 after the company priced 8 million shares at $9.25 per share.
Raptor Pharmaceuticals (NASDAQ: RPTP) was down, falling 20.45 percent to $11.77 after the company reported Q4 results. Raptor Pharmaceutical posted a Q4 loss of $0.20 per share, versus the projected loss of $0.16 per share.
Hot Japanese Companies To Buy Right Now: Digirad Corp (DRAD)
Digirad Corporation, incorporated in 1997, is the developer and manufacturer of medical diagnostic imaging systems, including solid-state gamma cameras for nuclear cardiology and general nuclear medicine applications. The Company operates in two segments: DIS (its diagnostic imaging service business) and its product segment. Through DIS, the Company provides in-office imaging services to physicians, offering certified personnel, required licensure, an imaging system and other support and supplies for the performance of nuclear and ultrasound imaging procedures under the supervision of its physician customers. The Companies imaging systems are sold in both portable and fixed configurations. DIS physician customers enter into annual lease contracts for imaging services generally delivered on a per-day basis. The Company�� product segment sells solid-state gamma cameras and provides camera service and maintenance.
Imaging Services
DIS offers portable nuclear and ultrasound imaging services. Its nuclear modality services include an imaging system, a certified nuclear medicine technologist and a cardiac stress technician, often certified or a trained nurse or paramedic, the supply of radiopharmaceuticals, and required licensing services for the performance of nuclear imaging procedures under the supervision of physicians. The ultrasound imaging service is similar, in that the Company provides the ultrasound equipment and one ultrasound technologist. Its portable nuclear imaging operations use a hub and spoke model, in which centrally located regional hubs anchor multiple van routes in the surrounding metropolitan areas. At its DIS hubs, clinical personnel load the equipment, radiopharmaceuticals, and other supplies onto specially equipped vans for transport to the physician�� office or other customer locations, where they set up the equipment for the day. The Company provides nuclear and ultrasound services primarily under annual contracts for services delivered on a per-day ! basis.
Products
Digirad markets and manufactures a line of nuclear medicine cameras for nuclear cardiology and general nuclear medicine applications. Its cameras are used in hospitals, imaging centers, physician offices and by mobile service providers. Its nuclear cameras feature detectors based on solid-state technology developed by the Company. The solid-state technology provides the Company with the capability to market and manufacture a diverse family of cardiac and general-purpose cameras.
The Cardius family of cardiac SPECT (single-photon emission computerized tomography) solid-state imagers makes it possible to image patients up to 500 pounds in a sitting position. Upright imaging makes it possible to image bariatric, COPD (chronic obstructive pulmonary disease) or claustrophobic patients that typically could not be imaged lying down on. The Company offers fixed dual-head and triple-head cardiac camera models for use within a facility and a portable dual-head configuration that makes it possible to move the system to provide service to multiple rooms or sites. Its flagship in cardiology is the Cardius XACT SPECT/CT system. It features a triple-head design and a low dose volume computed tomography (CT) attenuation correction methodology.
The Company�� ergo is a large-field-of-view planar portable imaging camera. The ergo imaging system is targeted to hospitals with multi-camera general nuclear medicine departments, academic centers, pediatric hospitals, regional trauma centers, women�� health centers and cancer centers. The Company also provides triple-head Cardius 3 XPO system, which provides shorter image acquisition time. Its Cardius X-ACT camera is a rapid cardiac SPECT/VCT imager. The Cardius X-ACT camera is positioned more toward the hospital and larger cardiology practices.
Advisors' Opinion:- [By Lisa Levin]
Digirad (NASDAQ: DRAD) shares created a new 52-week high of $3.989 on Q3 results.
Posted-In: 52-Week HighsNews Intraday Update Markets Movers
- [By John Kell and Tess Stynes var popups = dojo.query(".socialByline .popC"); p]
Digirad Corp.(DRAD) agreed to pay at least $3.5 million in cash to acquire medical-outsourcing provider Telerhythmics, a deal that will add to the larger company’s sales and bottom line.
Hot Japanese Companies To Buy Right Now: Heidrick & Struggles International Inc (HSII)
Heidrick & Struggles International, Inc. (Heidrick & Struggles) is an advisory firm providing executive search and leadership consulting services. As of December 31, 2011, the Company provided its services to a range of clients through the expertise of 347 consultants located in various cities around the world. The Company�� service offerings include executive search, leadership consulting and client base. The Company helps its clients build leadership teams by facilitating the recruitment, management and deployment of senior executives. In addition to executive search, it provides a range of leadership consulting services to clients. These services include succession planning, executive assessment, talent retention management, executive development, transition consulting for newly appointed executives, and mergers and acquisitions human capital integration consulting. In November 2013, Heidrick & Struggles International, Inc announced the acquisition of Scambler MacGregor.
The Company�� clients includes clients include Fortune 1000 companies, non-United States companies, middle market and emerging growth companies, governmental, higher education and not-for-profit organizations and other private and public entities. Heidrick & Struggles provides senior-level executive search and leadership consulting services to its clients worldwide through a network of more than 69 offices in 40 countries. The locations are staffed with consultants, research associates, administrative assistants and other support staff. Administrative functions are centralized where possible, although certain support and research functions are situated regionally because of variations in local requirements.
The Company�� worldwide network includes affiliate relationships in Finland, South Africa, Turkey and Portugal. It has no financial investment in these affiliates but receive licensing fees from them for the use of its name and its databases. Licensing fees are less than 1% of its net revenue. As ! of December 31, 2011, the Company had 160 consultants in its Americas segment, which included New York, Chicago and Atlanta. As of December 31, 2011, the Company had 104 consultants in its European segment, which included the United Kingdom, Germany and France. As of December 31, 2011, the Company had 83 consultants in itsAsia Pacific segment, which included China (including Hong Kong), Australia and Singapore. The Company�� executive search business operates in six broad industry groups: Financial Services, Industrial, Consumer Markets, Global Technology and Services, Life Sciences, and Education and Social Enterprise.
Its executive search consultants also specialize in searches for specific C-level functional positions, which are roles that generally report directly to the chief executive officer. These include chief financial officers, chief information officers, chief legal officers, chief marketing officers and chief human resources officers. The Company�� Global Functional Practices include Chief Executive Officer and Board of Directors; Chief Human Resources Officers; Financial Officers; Information Officers; Interim Executives; Legal, Risk, Compliance & Government Affairs; Marketing, Sales & Strategy Officers; Multicultural & Digital Marketing; Sales Officers; Research & Development; and Supply Chain & Transportation.
The Company competes with Egon Zehnder International, Korn/Ferry International, Russell Reynolds Associates, Inc. and Spencer Stuart & Associates.
Advisors' Opinion:- [By GuruFocus]
Heidrick & Struggles International Inc. (HSII): Interim CEO Jory J. Marino Bought 9,917 Shares
Interim CEO of Heidrick & Struggles International Inc. (HSII) Jory J. Marino bought 9,917 shares on 08/23/2013 at an average price of $15.03. Heidrick & Struggles International Inc. was formed as a Delaware corporation in 1999. Heidrick & Struggles International Inc. has a market cap of $272.497 million; its shares were traded at around $15.03 with a P/E ratio of 61.73 and P/S ratio of 0.58. The dividend yield of Heidrick & Struggles International Inc. stocks is 3.46%.
Hot Japanese Companies To Buy Right Now: Idenix Pharmaceuticals Inc.(IDIX)
Idenix Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs for the treatment of human viral diseases in the United States and Europe. Its primary research and development focus is on the treatment of patients with hepatitis C virus (HCV). The company?s HCV discovery program focuses on various classes of drugs, including nucleoside/nucleotide polymerase inhibitors, protease inhibitors, non-nucleoside polymerase inhibitors, and NS5A inhibitors. It develops products and drug candidates for the treatment of patients with hepatitis B virus (HBV), human immunodeficiency virus (HIV) type-1, and acquired immune deficiency syndrome (AIDS). The company principally has a collaboration agreement with Novartis Pharma AG for the development and commercialization of telbivudine, a drug for the treatment of HBV under the Tyzeka/Sebivo names. Idenix Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Advisors' Opinion:- [By Brian Orelli]
Idenix Pharmaceuticals (NASDAQ: IDIX ) just can't catch a break. The company is down nearly 30% today after announcing that the Food and Drug Administration won't let Idenix start a clinical trial for its hepatitis C drug IDX20963 until the company turns in additional preclinical safety data.
- [By John Udovich]
While Intercept Pharmaceuticals Inc (NASDAQ: ICPT) surged earlier this year and Achillion Pharmaceuticals, Inc (NASDAQ: ACHN) has surged this week after Merck & Co. Inc (NYSE: MRK) agreed to purchase hepatitis stock�Idenix Pharmaceuticals Inc (NASDAQ: IDIX) at a 239% premium, it seems the herd has realized that small cap Conatus Pharmaceuticals Inc (NASDAQ: CNAT) is also a liver disease stock as shares suddenly surged 56.69% on no apparent company news. But just what is�Conatus Pharmaceuticals and is it worth taking a chance on?
Hot Japanese Companies To Buy Right Now: Senesco Technologies Inc (SNTI)
Senesco Technologies, Inc., incorporated on September 30. 1999, is engaged in utilize its eukaryotic translation initiation Factor 5A, or Factor 5A, and deoxyhypusine synthase (DHS), and related technologies for human therapeutic applications to develop approaches to treat cancer and inflammatory diseases. In agricultural applications, the Company has licensed applications of the Factor 5A, DHS and Lipase platforms to develop the productivity of fruits, flowers, vegetables, agronomic and biofuel feedstock crops through the control of cell death and growth in plants.
Human Therapeutic Applications
The Company has developed a therapeutic candidate, SNS01-T, an improved formulation of SNS01, for the potential treatment of multiple myeloma and non-Hodgkin B-cell lymplomas. SNS01-T utilizes the Company's Factor 5A technology and consists of two components, which include a DNA plasmid (pDNA), expressing human eIF5A containing a lysine to arginine substitution at amino acid position 50, (eIF5AK50R), and a small inhibitory RNA (siRNA). These two components are combined in a fixed ratio with a polymer, polyethyleneimine (PEI), which enables self-assembly of the DNA and RNA into nanoparticles with demonstrated enhanced delivery to tissues and protection from degradation in the blood stream. The Company has also demonstrated that the combination of lenalidomide and SNS 01-T performs better than either treatment alone in mouses xenograft models of human mantle cell lymphoma. The Company's human therapeutic research program, which consists of pre-clinical in-vitro and in-vivo experiments designed to assess the role and mode of action of Factor 5A in human diseases and a phase 1a/2b clinical trial.
The Company competes with Celgene, Inc., Takeda/Millennium, ONYX Pharmaceuticals, Inc., Amgen Inc., Janssen Biotech, Inc., Novartis AG, and Pharmacyclics, Inc.
Agricultural Applications
The Company's agricultural research focuses on the discovery and develo! pment of certain gene technologies, which are designed to confer positive traits on fruits, flowers, vegetables, forestry species and agronomic crops. The Company's research and development initiatives for agriculture include develop and implement the DHS and Factor 5A gene technology in banana, canola, cotton, turfgrass, rice, alfalfa, corn, soybean and trees; and test the resultant crops for new beneficial traits such as increased yield, increased tolerance to environmental stress, disease resistance and more efficient use of fertilizer.
The Company competes with Mendel Biotechnology, Renessen LLC, Exelixis Plant Sciences, Inc., and Syngenta International AG.
Advisors' Opinion:- [By Peter Graham]
At the end of last week, small cap stocks Senesco Technologies, Inc (OTCBB: SNTI), VolitionRX Ltd (OTCMKTS: VNRX) and Micromem Technologies Inc (OTCBB: MMTIF) were all trending upwards ��ending up 13.65%, 8.73% and 7.61%, respectively, on Friday. However, it�� a new trading week with the last two trading days for the year. So what direction will these three small caps head in for the end of this year and into next year? Here is a quick look to help you decide on a trading or investment strategy:
- [By CRWE]
Today, SNTI has shed (-2.44%) down -0.0010 at $.0400 with�723,673 shares in play thus far (ref. google finance Delayed: 2:58PM EDT October 7, 2013).
Senesco Technologies, Inc. previously reported it has entered into a securities purchase agreement with certain investors to raise $1.725 million in gross proceeds through the sale of 69,000,000 shares of its common stock. The common stock was priced at $0.025 per share.
The offering is expected to close on or about October 2, 2013, subject to customary closing conditions. The net proceeds of the financing will be used primarily for working capital, research and development and general corporate purposes.
Hot Japanese Companies To Buy Right Now: Methanex Corporation (MEOH)
Methanex Corporation, together with its subsidiaries, engages in the production, marketing, and sale of methanol. The company also purchases and re-sells methanol produced by others. Its methanol is a clear liquid commodity chemical that is used to produce traditional chemical derivatives, including formaldehyde, acetic acid, and various other chemicals. The company�s methanol is also used in energy-related applications; for blending into gasoline, as a feedstock in the production of dimethyl ether, which can be blended with liquefied petroleum gas for use in household cooking and heating, and in the production of biodiesel; and used to produce methyl tertiary-butyl ether, a gasoline component, as well as used into olefins applications. The company supplies its methanol to petrochemical producers and distributors in North America, the Asia Pacific, Europe, and Latin America. Methanex Corporation was founded in 1968 and is headquartered in Vancouver, Canada.
Advisors' Opinion:- [By Holly LaFon]
His largest new buys in the first quarter are: Penn Virginia Group Holdings LP (PVG), Wynn Resorts Ltd. (WYNN), Methanex Corp. (MEOH), Solutia Inc. (SOA) and Georgia Gulf (GGC). Of his top eight stocks, five are from the chemicals industry.
No comments:
Post a Comment